1. Home
  2. CDXS vs ELTX Comparison

CDXS vs ELTX Comparison

Compare CDXS & ELTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Codexis Inc.

CDXS

Codexis Inc.

HOLD

Current Price

$1.25

Market Cap

141.8M

Sector

Industrials

ML Signal

HOLD

Logo Elicio Therapeutics Inc.

ELTX

Elicio Therapeutics Inc.

HOLD

Current Price

$11.63

Market Cap

134.1M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
CDXS
ELTX
Founded
2002
2011
Country
United States
United States
Employees
N/A
N/A
Industry
Major Chemicals
Biotechnology: Pharmaceutical Preparations
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
141.8M
134.1M
IPO Year
2008
2014

Fundamental Metrics

Financial Performance
Metric
CDXS
ELTX
Price
$1.25
$11.63
Analyst Decision
Strong Buy
Analyst Count
0
1
Target Price
N/A
$13.00
AVG Volume (30 Days)
1.5M
144.3K
Earning Date
01-01-0001
01-01-0001
Dividend Yield
N/A
N/A
EPS Growth
20.54
38.94
EPS
N/A
N/A
Revenue
$138,590,000.00
$2,301,000.00
Revenue This Year
$15.64
N/A
Revenue Next Year
$5.23
N/A
P/E Ratio
N/A
N/A
Revenue Growth
32.30
N/A
52 Week Low
$0.96
$4.60
52 Week High
$3.87
$14.93

Technical Indicators

Market Signals
Indicator
CDXS
ELTX
Relative Strength Index (RSI) 49.23 61.43
Support Level $1.17 $7.78
Resistance Level $1.24 $12.52
Average True Range (ATR) 0.10 1.05
MACD 0.03 0.19
Stochastic Oscillator 77.41 50.00

Price Performance

Historical Comparison
CDXS
ELTX

About CDXS Codexis Inc.

Codexis Inc is a provider of enzymatic solutions for efficient and scalable therapeutics manufacturing that leverages its proprietary CodeEvolver technology platform to discover, develop, and enhance novel, high-performance enzymes. Codexis enzymes solve challenges associated with small molecule pharmaceuticals manufacturing and nucleic acid synthesis. The Company is currently developing its proprietary ECO Synthesis manufacturing platform to enable the scaled manufacture of RNAi therapeutics through an enzymatic route. Codexis' enzymes can drive improvements such as higher yields, reduced energy usage and waste generation, improved efficiency in manufacturing and greater sensitivity in genomic and diagnostic applications. Geographically, it derives maximum revenue from the Americas.

About ELTX Elicio Therapeutics Inc.

Elicio Therapeutics Inc is a clinical-stage biotechnology company pioneering the development of cancer immunotherapies for patients with limited treatment options and poor outcomes. Its proprietary Amphiphile, or AMP, platform delivers investigational immunotherapeutics directly to the brain center of the immune system the lymph nodes. Its focus is the development of cancer immunotherapies against biologically validated but hard-to-drug targets that can be activated through lymph node trafficking.

Share on Social Networks: